Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy

1. Auflage 2020
ISBN: 978-981-15-8181-6
Verlag: Springer

Buch, Englisch, 258 Seiten, Format (B × H): 155 mm x 235 mm, Gewicht: 423 g

This book reviews the latest developments in the design, synthesis, and molecular mechanism of action of Histone Deacetylase (HDAC) inhibitors in the context of potential cancer therapy. HDAC inhibitors are emerging as promising anticancer drug molecules that promote growth arrest, differentiation and apoptosis of cancer cells with tumor selective toxicity.

The book begins with an overview of various epigenetic modifying enzymes that are involved in cancer transition and progression; before exploring the potential of HDACs in cancer treatment. It provides a classification of HDAC inhibitors based on their structural attributes, and addresses HDAC-induced cytotoxicity..

Lastly, it discusses and assesses the rationale behind therapies that combine HDAC inhibitors with other anticancer agents to treat solid tumors. Given its scope, it offers a valuable resource for all researchers, clinicians, and students working in formulation, drug discovery, oncology, and personalized medicine.

Zielgruppe

Research

Autoren/Hrsg.

Ganai, Shabir Ahmad

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Vorklinische Medizin: Grundlagenfächer Humangenetik
• Naturwissenschaften Biowissenschaften Biochemie (nichtmedizinisch)

Inhaltsverzeichnis

Chapter 1_ Epigenetic modifying enzymes . -Chapter 2_ Epigenetic modifying enzymes implicated in cancer . -Chapter 3_ Classification of histone deacetylases (HDACs) . -Chapter 4_ Implications of 18 HDAC isoforms in therapeutically monotonous cancers . –Chapter 5_ Possible Mechanisms of HDACs in Cancer development.-  Chapter 6_ Different strategies employed for circumventing cancer resistance (chemo and radio) and mitigating toxicity.  -Chapter 7_ Limitations of conventional therapeutic regimens in treating cancer. - Chapter 8 _Overview of epidrugs with special emphasis on HDAC inhibitors (HDACi).-  Chapter 9 _HDAC inhibitors as promising epidrugs for treating cancer. - Chapter 10_  HDAC inhibitors in anticancer monotherapy . -Chapter 11_ Distinct groups of histone deacetylase inhibitors (HDACi) based on the structural distinction, HDACs targeted. - Chapter 12_ Limited efficacy of HDAC inhibitor-based monotherapy. - Chapter 13_ Resistance mechanisms generated by cancer cells against HDACi based monotherapy. - Chapter 14_  Toxicity issue of HDAC inhibitor based monotherapy. - Chapter 15_ Combinatorial therapeutic strategies of HDACi. - Chapter 16_ Designing Selective HDACi using computational and medicinal chemistry approach. - Chapter 17.  Current therapeutic challenges and future directions.

Über Autor(innen)

Dr. Shabir Ahmad Ganai  has formerly worked as Principal Investigator/Young Scientist in the University of Kashmir. He has over 9 years of working experience in the field of histone deacetylases and histone deacetylase inhibitors. He has published more than 24 articles in highly reputed international journals, 3 international book chapters and has authored a book. He is currently serving as a referee for various international journals like Scientific Reports, PLOS ONE, Medicinal Chemistry Research, Current Drug Targets, Current Topics in Medicinal Chemistry, and Journal of Agricultural and Food Chemistry (American Chemical Society Publications). He is a member of two international societies, including the Epigenetics Society.